US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.12

-0.3100-1.32%

Post-market: 23.120.00000.00%19:30 EDT

Volume:511.97K

Turnover:11.76M

Market Cap:1.53B

PE:-7.43

High:23.51

Open:23.35

Low:22.61

Close:23.43

52wk High:30.99

52wk Low:10.30

Shares:66.17M

Float Shares:36.76M

Volume Ratio:1.03

T/O Rate:1.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1097

EPS(LYR):-2.5230

ROE:-41.01%

ROA:-26.14%

PB:3.26

PE(LYR):-9.16

Loading ...

Overview Company News Filings

Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)

Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss

MT Newswires Live

Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million

Bicara Therapeutics Q4 EPS $(0.68), Inline

Benzinga Earnings

Stock Track | Bicara Therapeutics Soars 5.55% in Pre-market on Earnings Report Release

Bicara Therapeutics Inc - Q4 Net Loss $37.4 Mln; FY2025 Net Loss $138.0 Mln

THOMSON REUTERS

Bicara Therapeutics: Initiated Phase 3 of the Fortifi-Hn01 Pivotal Trial; Interim Analysis Expected Mid-2027

THOMSON REUTERS

Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit

Bicara Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229

BofA Initiates Bicara Therapeutics at Buy With $35 Price Target

MT Newswires Live

Bicara Therapeutics Initiated at Buy by B of A Securities

Bicara Therapeutics initiated with a Buy at BofA

Calendar of U.S. Earnings Expected in the Week Ahead

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BCAX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":23.12,"timestamp":1788206400000,"preClose":23.43,"halted":0,"volume":511965,"hourTrading":{"tag":"盘后","latestPrice":23.12,"preClose":23.12,"latestTime":"19:30 EDT","volume":14454,"amount":334177.36004,"timestamp":1788219002960,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.013230900554844162,"floatShares":36762300,"shares":66172934,"eps":-3.109661,"marketStatus":"Not Yet Opened","change":-0.31,"latestTime":"08-31 16:00:00 EDT","open":23.35,"high":23.505,"low":22.61,"amount":11760543.58563,"amplitude":0.038199,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":23.43,"preHourTrading":{"tag":"盘前","latestPrice":23,"preClose":23.43,"latestTime":"09:24 EDT","volume":14,"amount":333.499012,"timestamp":1788182690099,"change":-0.43,"changeRate":-0.018353,"amplitude":0.042676},"postHourTrading":{"tag":"盘后","latestPrice":23.12,"preClose":23.12,"latestTime":"19:30 EDT","volume":14454,"amount":334177.36004,"timestamp":1788219002960,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.034854,"impliedVol":0.3535,"impliedVolPercentile":0.5299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":36762300,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":1.034854,"shares":66172934,"dividePrice":0,"high":23.505,"amplitude":0.038199,"preClose":23.43,"low":22.61,"week52Low":10.295,"pbRate":"3.26","week52High":30.99,"institutionHeld":0,"latestPrice":23.12,"eps":-3.109661,"divideRate":0,"volume":511965,"delay":0,"ttmEps":-3.109661,"open":23.35,"prevYearClose":16.83,"prevWeekClose":23.43,"prevMonthClose":27.1,"prevQuarterClose":29.69,"fiveDayClose":23.58,"twentyDayClose":25.74,"sixtyDayClose":20.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3125,"buy":0.5,"hold":0.1875,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":16,"updateTime":1787284800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-08-28","current":-7.434894,"percent":0.572597,"low":-22.704836,"twenty":-12.269802,"median":-9.54708,"eighty":-6.936947,"high":-5.144536,"avg":-10.492201,"sd":4.112822,"marketCap":1643073951},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860},{"date":"2026-08-28","current":-8.864088,"twenty":-12.269802,"median":-9.54708,"eighty":-6.936947,"marketCap":1643073951}],"updateTime":1788242812992},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623312822","title":"Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312822","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312822?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:41","pubTimestamp":1774870881,"startTime":"0","endTime":"0","summary":"As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q4-eps-68c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q4-eps-68c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623147863","title":"Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2623147863","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623147863?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:38","pubTimestamp":1774870687,"startTime":"0","endTime":"0","summary":"Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314210","title":"Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314210?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:34","pubTimestamp":1774870442,"startTime":"0","endTime":"0","summary":"Bicara posted a Q4 net loss of USD 37 million, more than doubled from a year earlier.Full-year net loss widened to USD 140 million, while R&D spending climbed to USD 130 million due to costs tied to the FORTIFI-HN01 pivotal trial, Phase 1/1b expansion cohorts, and higher personnel expense.Cash, cash equivalents, and marketable securities totaled USD 410 million at year-end; an oversubscribed offering added USD 160 million in net proceeds in Q1.Phase 3 of the FORTIFI-HN01 study started with 1,500 mg weekly ficerafusp alfa selected as the optimal dose; interim analysis expected mid-2027.Company expects existing cash, cash equivalents, and marketable securities to fund operations into the first half of 2029.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2lJjgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BCAX","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231443","title":"Bicara Therapeutics Q4 EPS $(0.68), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231443","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231443?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:33","pubTimestamp":1774870397,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51535064/bicara-therapeutics-q4-eps-0-68-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183833054","title":"Stock Track | Bicara Therapeutics Soars 5.55% in Pre-market on Earnings Report Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1183833054","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183833054?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:32","pubTimestamp":1774870367,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics' stock surged 5.55% during pre-market trading on Monday, following the release of its fourth quarter and full year 2025 financial results and business update.The company was...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623731448","title":"Bicara Therapeutics Inc - Q4 Net Loss $37.4 Mln; FY2025 Net Loss $138.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731448?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9GLT2C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623415314","title":"Bicara Therapeutics: Initiated Phase 3 of the Fortifi-Hn01 Pivotal Trial; Interim Analysis Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2623415314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623415314?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9GLT2C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314495","title":"Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314495?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027. Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa. Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET. BOSTON, March 30, 2026  -- Bicara Therapeutics Inc.  today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update.\"Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities,\" said Claire Mazumdar, Ph.D., Chief Executive Officer at Bicara Therapeutics. \"The continued advancement of our pivotal FORTIFI-HN01 study, the robust body of clinical data supporting ficerafusp alfa's differentiated profile, and the alternate dosing option for ficerafusp alfa all underscore the significant progress we've made toward transf","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0269904917.USD","IE00BYTNYN87.SGD","BK4509","BCAX","LU2039709279.SGD","01698","LU0359201612.USD","IE00BYQNZ168.SGD","BK4535","LU1023057109.AUD","BK4526","BK4139","LU0828238088.HKD","BK4531","IE00B12V2V27.USD","BK4108","SG9999011746.SGD","BK4552","LU0359202008.SGD","BK4571","LU0456842615.SGD","BK4565","BK4563","LU0509642566.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BTBT","MKC.V","BEEM","MSM","AEHR","BITF","FC","PVLA","BNZI","PHR","AIRO","JILL","APOG","KEEL","PRGS","PLAY","BCAX","NCNO","AIRJ","NNOX","BIRD","AYI","CALM","CAG","NEOG","NGEN","RNXT","PROP","CRDL","BYND","MAZE","AURA","PENG","FDS","BHST","PRPL","ANGO","SGML","MKC","SGMO","DMAC","INMB","INV","NKE","NMRA","RH","LNN","LW","NKLR","PVH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622980815","title":"Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622980815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622980815?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:30","pubTimestamp":1774643400,"startTime":"0","endTime":"0","summary":"Canada recorded a deficit in January similar to the year-ago period, as both tax revenue and government spending declined in the month.Canada had a budget deficit of C$5.07 billion in January, the Department of Finance said Friday in its monthly Fiscal Monitor publication. This is largely in line with the C$5.13 billion deficit posted in January of last year. With just two months left in the 2025-26 fiscal year, Canada's budget deficit sits at C$31.21 billion, an increase of about 16% from the comparable year-ago period.The Liberal government's annual budget plan, issued in November, projected a C$78.3 billion deficit in the current fiscal year. Historically, finance ministry data tends to show sizable deficits in the month of March, or the last month of the fiscal year, due to adjustments to tax receipts.Statistics Canada Estimates Wholesale Trade Rose 2.3% in February. The estimate incorporates wholesale transactions excluding petroleum products, oilseeds and grains. The data agency ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HQI","BK4120","GNE","BK4139","BCAX","IEF","CYCN","BK4097","BK4079","INLX","AQMS","BCLI","BK4161","CFA.SI","FTHM","BK4585","AIRJ","BK4081","CVV","GALT","ANNX","BK4130","BK4588","BK4147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873091","title":"Bicara Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622873091?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:14","pubTimestamp":1774624485,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Bicara Therapeutics Inc BCAX.OQ BCAX.O is expected to  show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANGO","KOPN","NKLR","BEEM","BHST","CRDL","AIRO","NEOG","CCL","AUTL","AYI","INMB","APOG","LNN","CALM","NKE","CAG","AEHR","HUMA","NMRA","BTBT","KYTX","MSLE","JILL","DMAC","PHR","PENG","RNXT","BYND","MKC.V","PRGS","DEFT","BIRD","IMNN","BCAX","LW","ATOS","BITF","FC","LGN","AIRJ","FDS","PLAY","NCNO","MSM","KEEL","AURA","NGEN","BNZI","INV","MKC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622975808","title":"Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229","url":"https://stock-news.laohu8.com/highlight/detail?id=2622975808","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622975808?lang=en_us&edition=fundamental","pubTime":"2026-03-27 07:21","pubTimestamp":1774567316,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer at Bicara Therapeutics, reported transactions in the company’s common stock on 03/25/2026.He exercised stock options for 5,500 shares at USD 3.79 per share.He sold 5,500 shares at a weighted average price of USD 18.95 per share.Following the transactions, he reported direct ownership of 55,286 common shares.He also reported 47,413 stock options outstanding after the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5h0RQp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622506074","title":"BofA Initiates Bicara Therapeutics at Buy With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622506074","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622506074?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:04","pubTimestamp":1774447461,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $29.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622760600","title":"Bicara Therapeutics Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2622760600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622760600?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:58","pubTimestamp":1774443480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 08:58 ET (12:58 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622022366","title":"Bicara Therapeutics initiated with a Buy at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2622022366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622022366?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:10","pubTimestamp":1774433452,"startTime":"0","endTime":"0","summary":"BofA initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $35 price target Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","DEFT","AGX","BITF","BYND","DERM","ABOS","KOD","CNTX","DOO","AUTL","AURA","BHST","HYPD","JEF","BAK","CNTB","AIRO","CMC","EPAC","CGTX","IMNN","EDAP","BCAX","BNZI","FDS","CCL","FEMY","FUL","BTGO","BIRD","CHWY","EQ","KALV","CELC","JILL","RNXT","CDLR","MKC","CTAS","GOVX","IKT","CGNT","JBS","HUMA","AIRJ","IMDX","NKE","DMAC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DK","CVI","BZAI","FIG","AIR","AARD","AFG","INSM","FANG","AMZP","AMZD","BXP","CVX","FIGG","AVTX","CDE","EVGO","GLW","ESE","HD","BPH","USAW.SI","DG","APEI","BRZE","GENB","HAL","ABSI","AZYY","BP","CEGX","CEG","AMZU","BCAX","BTM","ARE","KBH","DINO","ADUS","AMZN","BAM","MTDR","ACAD","ELVN","BWXT","CNM","AVAH","FRPT","CALM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622014384","title":"Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014384","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622014384?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:45","pubTimestamp":1774395930,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics, reported an option exercise for 9,200 common shares at USD 3.79 per share.He also reported selling 9,200 common shares at a weighted average price of USD 18.52 per share.Following the transactions, he beneficially owned 145,355 common shares.After the option exercise, he held 48,944 stock options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5Q42FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara CFO Ivan Hyep disposed of USD 170,348 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621672705","title":"Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2621672705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621672705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:30","pubTimestamp":1774269000,"startTime":"0","endTime":"0","summary":"BOSTON, March  23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260367/0/en/Bicara-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates-on-March-30-2026-at-8-30-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ET","IE00BZ18W340.USD","IE00BMQBXF63.USD","BCAX","IE00BZ18W456.USD","BK4590","BK4588","AM","BK4144","BK4581","BK4139","BK4561","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":138,"code":"91000000","status":"200"}]}}